Nuance Investments LLC Cuts Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

Key Points

• Nuance Investments LLC has reduced its holdings in Henry Schein, Inc. by 53.8%, now owning 910,463 shares, which makes up 4.1% of their portfolio.
• Henry Schein reported $1.10 earnings per share for the last quarter, which missed analysts’ expectations of $1.19 and showed a year-over-year revenue growth of 3.3%.
• Wall Street analysts have recently adjusted their price targets for Henry Schein, with an average target price of $75.58 and a consensus rating of "Hold."

Nuance Investments LLC reduced its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 53.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 910,463 shares of the company's stock after selling 1,058,703 shares during the quarter. Henry Schein comprises approximately 4.1% of Nuance Investments LLC's portfolio, making the stock its 10th largest holding. Nuance Investments LLC owned about 0.75% of Henry Schein worth $62,358,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Guggenheim Capital LLC boosted its holdings in shares of Henry Schein by 2.5% in the fourth quarter. Guggenheim Capital LLC now owns 6,428 shares of the company's stock valued at $445,000 after acquiring an additional 159 shares in the last quarter. UMB Bank n.a. boosted its holdings in Henry Schein by 23.2% during the first quarter. UMB Bank n.a. now owns 1,066 shares of the company's stock worth $73,000 after buying an additional 201 shares in the last quarter. Humankind Investments LLC lifted its holdings in shares of Henry Schein by 7.4% in the fourth quarter. Humankind Investments LLC now owns 3,057 shares of the company's stock valued at $212,000 after purchasing an additional 211 shares in the last quarter. HB Wealth Management LLC lifted its holdings in shares of Henry Schein by 1.5% in the first quarter. HB Wealth Management LLC now owns 15,419 shares of the company's stock valued at $1,056,000 after purchasing an additional 226 shares in the last quarter. Finally, J. Safra Sarasin Holding AG lifted its holdings in shares of Henry Schein by 1.1% in the fourth quarter. J. Safra Sarasin Holding AG now owns 22,098 shares of the company's stock valued at $1,529,000 after purchasing an additional 231 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Stock Up 2.2%

Shares of HSIC traded up $1.49 during midday trading on Wednesday, hitting $68.99. The company had a trading volume of 1,892,260 shares, compared to its average volume of 2,053,081. The company's 50 day moving average price is $70.91 and its 200 day moving average price is $70.96. The stock has a market cap of $8.37 billion, a price-to-earnings ratio of 22.25, a PEG ratio of 2.23 and a beta of 0.81. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $82.49. The company has a quick ratio of 0.78, a current ratio of 1.41 and a debt-to-equity ratio of 0.51.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.19 by ($0.09). Henry Schein had a return on equity of 14.36% and a net margin of 3.05%. The business had revenue of $3.24 billion during the quarter, compared to the consensus estimate of $3.22 billion. During the same quarter in the previous year, the business posted $1.23 earnings per share. The company's quarterly revenue was up 3.3% compared to the same quarter last year. On average, equities research analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Evercore ISI cut their price objective on shares of Henry Schein from $78.00 to $70.00 and set an "in-line" rating for the company in a research report on Wednesday, August 6th. JPMorgan Chase & Co. cut their price objective on shares of Henry Schein from $80.00 to $76.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. Wells Fargo & Company cut their price objective on shares of Henry Schein from $80.00 to $75.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Robert W. Baird reissued a "neutral" rating and issued a $72.00 price objective (down previously from $82.00) on shares of Henry Schein in a research report on Monday, July 14th. Finally, UBS Group dropped their price target on shares of Henry Schein from $75.00 to $70.00 and set a "neutral" rating for the company in a research report on Wednesday, August 6th. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $75.58.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.